{
    "hands_on_practices": [
        {
            "introduction": "Accurate diagnosis and management of thyroid disorders depend critically on the correct interpretation of thyroid function tests. However, the biochemical methods underlying these tests are susceptible to interference, a pitfall that can lead to significant diagnostic error. This exercise explores the clinically important interference caused by high-dose biotin supplements, which can create a laboratory pattern that deceptively mimics primary hyperthyroidism. By understanding the mechanisms of sandwich versus competitive immunoassays , you will develop the crucial skill of critically evaluating discordant lab results before initiating potentially harmful treatments.",
            "id": "4905746",
            "problem": "A clinical laboratory uses streptavidin–biotin capture in its thyroid panel. Thyroid-Stimulating Hormone (TSH) is measured by a two-site sandwich immunoassay in which a biotinylated capture antibody and a labeled detection antibody form a ternary immunocomplex with antigen, and the complex is immobilized via streptavidin. Free Thyroxine (fT4) is measured by a one-step competitive immunoassay in which endogenous fT4 competes with a labeled, biotinylated thyroxine analog for a finite number of antibody binding sites; the antibody–tracer complex is immobilized by streptavidin for signal generation. A patient begins a high-dose biotin supplement and has blood drawn shortly thereafter.\n\nUsing fundamental properties of streptavidin–biotin binding and immunoassay signal relationships, answer the following. First, define and explain biotin-induced assay interference in the context of sandwich immunoassays that rely on streptavidin–biotin capture. Then, predict the direction of error in the measured results for Thyroid-Stimulating Hormone (TSH) and Free Thyroxine (fT4) under significant circulating biotin exposure. Your reasoning should start from the following foundational facts:\n\n- The streptavidin–biotin interaction has extremely high affinity, with dissociation constant $K_d \\approx 10^{-14}\\,\\mathrm{M}$, and is exploited to immobilize biotinylated assay components.\n- In sandwich immunoassays, the measured signal is directly proportional to analyte concentration $C_a$ because more analyte generates more captured immunocomplex.\n- In competitive immunoassays, the measured signal is inversely proportional to analyte concentration $C_a$ because more analyte displaces labeled tracer from antibody binding sites, reducing captured tracer.\n\nWhich option best states the mechanism of biotin-induced interference in these assays and correctly predicts the direction of error in TSH and fT4?\n\nA. Excess circulating biotin occupies streptavidin sites, preventing efficient capture of biotinylated immunocomplexes. This reduces captured complex and signal in the TSH sandwich assay, yielding falsely low TSH. In the fT4 competitive assay, reduced capture of biotinylated tracer decreases signal, which the inverse calibration interprets as higher analyte, yielding falsely high fT4.\n\nB. Excess circulating biotin enhances binding of biotinylated immunocomponents to streptavidin via mass action, increasing signal in the TSH sandwich assay (falsely high TSH) and decreasing signal in the fT4 competitive assay (falsely low fT4).\n\nC. Excess circulating biotin reduces capture equally in both assays and therefore yields falsely low results for both TSH and fT4.\n\nD. Excess circulating biotin causes non-specific binding of detection reagents, increasing background signal and yielding falsely high TSH and falsely high fT4 regardless of assay format.",
            "solution": "The problem statement is evaluated as valid. It is scientifically grounded, well-posed, objective, and contains sufficient information to derive a unique solution based on established principles of immunoassay design and biochemistry.\n\n### Part 1: Mechanism of Biotin-Induced Assay Interference\n\nThe fundamental mechanism of interference arises from the presence of a high concentration of free, unbound biotin in the patient's sample. Both described immunoassays rely on the streptavidin–biotin interaction for a critical step: the immobilization of an immunocomplex onto a solid phase (e.g., a microparticle or microplate well).\n\n1.  **Streptavidin Binding Sites**: The solid phase in these assays is coated with streptavidin. Streptavidin possesses four high-affinity binding sites for biotin. The dissociation constant ($K_d$) for this interaction is extremely low, on the order of $10^{-14}\\,\\mathrm{M}$, indicating a nearly irreversible bond.\n2.  **Competition**: When a sample containing a high concentration of free biotin is introduced into the assay system, this exogenous biotin competes with the biotinylated reagents of the assay for the limited number of binding sites on the streptavidin-coated solid phase.\n3.  **Saturation**: Due to its high concentration and the strength of the interaction, the free biotin from the sample rapidly occupies or saturates the available streptavidin binding sites.\n4.  **Capture Inhibition**: Consequently, the intended biotinylated assay components—the capture antibody complex in the TSH assay or the antibody-tracer complex in the fT4 assay—are unable to bind efficiently to the solid phase. These uncaptured complexes are then removed during the subsequent wash steps. The net effect is a significant reduction in the amount of signal-generating complex that is immobilized on the solid phase.\n\n### Part 2: Prediction of Error for Thyroid-Stimulating Hormone (TSH)\n\nThe TSH assay is a two-site sandwich immunoassay. The key steps are:\n-   Patient TSH (antigen, $C_a$) binds to a biotinylated capture antibody and a labeled detection antibody, forming a ternary \"sandwich\" complex: [Biotin-CaptureAb]–[TSH]–[Labeled-DetectionAb].\n-   This complex is immobilized on the streptavidin-coated solid phase via the biotin on the capture antibody.\n-   The measured signal is directly proportional to the amount of captured complex, and therefore, directly proportional to the TSH concentration, $C_a$. We can represent this relationship as $S \\propto C_a$.\n\n**Effect of Biotin Interference**:\n-   As established in Part 1, excess free biotin in the sample saturates the streptavidin sites on the solid phase.\n-   This prevents the [Biotin-CaptureAb]–[TSH]–[Labeled-DetectionAb] complex from being captured.\n-   The amount of captured complex is therefore reduced, leading to a\n    **decrease in the measured signal** ($S$).\n-   Because the calibration curve for a sandwich assay interprets a lower signal as a lower concentration, the instrument reports a **falsely low TSH result**.\n\n### Part 3: Prediction of Error for Free Thyroxine (fT4)\n\nThe fT4 assay is a one-step competitive immunoassay. The key steps are:\n-   Endogenous fT4 from the patient's sample ($C_a$) competes with a known amount of a labeled, biotinylated thyroxine analog (the tracer, $T^*$) for a limited number of antibody binding sites.\n-   After the competition phase, the resultant antibody-tracer complexes, [Ab]–[$T^*$], are captured onto the streptavidin-coated solid phase.\n-   The measured signal is generated by the captured tracer. High levels of endogenous fT4 will outcompete the tracer, leading to fewer captured [Ab]–[$T^*$] complexes and a lower signal.\n-   Therefore, the measured signal is inversely proportional to the fT4 concentration, $C_a$. We can represent this relationship as $S \\propto 1/C_a$.\n\n**Effect of Biotin Interference**:\n-   As in the TSH assay, excess free biotin saturates the streptavidin sites.\n-   This prevents the biotinylated [Ab]–[$T^*$] complex from being captured, regardless of how much was formed during the competition step.\n-   The amount of captured tracer complex is therefore reduced, leading to a\n    **decrease in the measured signal** ($S$).\n-   Because the calibration curve for a competitive assay interprets a lower signal as a *higher* concentration (less signal implies more patient analyte was present to displace the tracer), the instrument reports a **falsely high fT4 result**.\n\n### Evaluation of Options\n\n**A. Excess circulating biotin occupies streptavidin sites, preventing efficient capture of biotinylated immunocomplexes. This reduces captured complex and signal in the TSH sandwich assay, yielding falsely low TSH. In the fT4 competitive assay, reduced capture of biotinylated tracer decreases signal, which the inverse calibration interprets as higher analyte, yielding falsely high fT4.**\n-   **Mechanism**: The description of interference is correct. Free biotin competitively inhibits the capture of biotinylated reagents by occupying streptavidin sites.\n-   **TSH Prediction**: \"falsely low TSH\" is the correct outcome for a sandwich assay with reduced signal.\n-   **fT4 Prediction**: \"falsely high fT4\" is the correct outcome for a competitive assay with reduced signal.\n-   **Verdict**: **Correct**.\n\n**B. Excess circulating biotin enhances binding of biotinylated immunocomponents to streptavidin via mass action, increasing signal in the TSH sandwich assay (falsely high TSH) and decreasing signal in the fT4 competitive assay (falsely low fT4).**\n-   **Mechanism**: This is fundamentally incorrect. Free biotin competes with, and thus inhibits, the binding of biotinylated reagents; it does not enhance it.\n-   **TSH/fT4 Predictions**: The predictions are based on this flawed premise and are therefore incorrect.\n-   **Verdict**: **Incorrect**.\n\n**C. Excess circulating biotin reduces capture equally in both assays and therefore yields falsely low results for both TSH and fT4.**\n-   **Mechanism**: It correctly states that biotin reduces capture in both assays.\n-   **Prediction**: It correctly predicts a falsely low TSH. However, it incorrectly predicts a falsely low fT4. It fails to account for the inverse relationship between signal and concentration in the competitive fT4 assay. A reduced signal in that format leads to a falsely high result.\n-   **Verdict**: **Incorrect**.\n\n**D. Excess circulating biotin causes non-specific binding of detection reagents, increasing background signal and yielding falsely high TSH and falsely high fT4 regardless of assay format.**\n-   **Mechanism**: The primary interference mechanism is competitive inhibition at the streptavidin site, not an increase in non-specific binding. This leads to a *decrease* in specific signal, not an increase in background signal.\n-   **Prediction**: The predictions of high TSH and high fT4 are based on an incorrect mechanism. The signal is decreased, not increased.\n-   **Verdict**: **Incorrect**.",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "The cornerstone of treating hypothyroidism is levothyroxine replacement therapy, typically initiated with a weight-based dose. Effective management, however, requires an understanding of pharmacokinetic principles that go beyond this initial calculation, particularly factors affecting drug absorption. This problem  presents a common clinical scenario where a patient's medication regimen includes a substance known to reduce levothyroxine bioavailability. This practice will guide you through quantitatively adjusting a dose to compensate for this interaction, a vital skill for achieving and maintaining euthyroidism in complex patients.",
            "id": "4905799",
            "problem": "A $32$-year-old healthy adult with overt primary hypothyroidism weighs $70 \\,\\mathrm{kg}$ and has no cardiovascular disease, is not pregnant, and takes no interacting medications other than calcium carbonate for dyspepsia. The patient takes levothyroxine and calcium carbonate simultaneously every morning, and cannot separate the dosing times. It is established from controlled pharmacokinetic studies that concurrent calcium carbonate ingestion reduces the oral bioavailability of levothyroxine such that only $0.72$ of the administered dose is absorbed compared with fasting administration. Using widely accepted internal medicine principles for full-replacement initial dosing of levothyroxine in healthy adults, first determine the initial full-replacement dose appropriate for this patient and then compute the adjusted daily dose that compensates for the $0.72$ bioavailability when co-administered with calcium carbonate, assuming the therapeutic goal is to achieve the same absorbed amount as under fasting conditions. Round your final adjusted dose to $4$ significant figures and express your answer in micrograms per day.",
            "solution": "The problem shall first be subjected to a rigorous validation procedure before any attempt at a solution is made.\n\n### Step 1: Extract Givens\n- Patient age: $32$ years\n- Patient condition: healthy adult with overt primary hypothyroidism\n- Patient weight: $W = 70 \\,\\mathrm{kg}$\n- Comorbidities: no cardiovascular disease\n- Special conditions: not pregnant\n- Interacting medications: calcium carbonate for dyspepsia\n- Dosing schedule: levothyroxine and calcium carbonate are taken simultaneously\n- Pharmacokinetic interaction: concurrent calcium carbonate ingestion reduces the oral bioavailability of levothyroxine to a fraction $f = 0.72$ of the bioavailability under fasting conditions.\n- Dosing principle to be used: \"widely accepted internal medicine principles for full-replacement initial dosing of levothyroxine in healthy adults\"\n- Therapeutic goal: achieve the same absorbed amount of levothyroxine as would be absorbed from the ideal fasting dose.\n- Required precision: round the final adjusted dose to $4$ significant figures.\n- Required units for final answer: micrograms per day ($\\mu\\mathrm{g/day}$).\n\n### Step 2: Validate Using Extracted Givens\nThe problem is subjected to validation based on the established criteria.\n\n1.  **Scientific Grounding**: The problem is scientifically grounded. The scenario describes a standard clinical case of primary hypothyroidism. The use of weight-based dosing for levothyroxine is the cornerstone of replacement therapy. The specified dosing guideline, \"widely accepted internal medicine principles,\" directly corresponds to the standard-of-care initial dose of approximately $1.6 \\,\\mu\\mathrm{g}/\\mathrm{kg}/\\mathrm{day}$ of ideal body weight for young, healthy adults. The interaction between levothyroxine and calcium salts, which chelate the hormone and reduce its gastrointestinal absorption, is a well-documented and clinically significant pharmacokinetic phenomenon. The stated bioavailability reduction factor of $f=0.72$ is a plausible value for this interaction.\n2.  **Well-Posedness**: The problem is well-posed. It provides all necessary quantitative data (patient weight $W=70\\,\\mathrm{kg}$, bioavailability factor $f=0.72$) and a clear reference to a standard, non-ambiguous clinical guideline for determining the initial dose. The objective is clearly defined: calculate an adjusted dose to compensate for reduced absorption. The path to a unique, stable, and meaningful solution is unambiguous.\n3.  **Objectivity**: The problem is stated in objective, formal language, free of subjective or opinion-based claims.\n\n### Step 3: Verdict and Action\nThe problem is deemed **valid**. It is scientifically sound, well-posed, objective, and internally consistent. The solution process may proceed.\n\nThe solution is a two-step process. First, we determine the ideal full-replacement dose of levothyroxine for the patient under fasting conditions. Second, we adjust this dose to account for the reduced bioavailability caused by co-administration with calcium carbonate.\n\n**Step 1: Determine the Ideal Full-Replacement Dose ($D_{\\text{ideal}}$)**\n\nThe \"widely accepted internal medicine principle\" for the initial full-replacement dose of levothyroxine in a young, healthy adult with overt hypothyroidism is a weight-based dose of $1.6 \\,\\mu\\mathrm{g}/\\mathrm{kg}/\\mathrm{day}$.\n\nGiven a patient weight of $W = 70 \\,\\mathrm{kg}$, the ideal daily dose, $D_{\\text{ideal}}$, is calculated as:\n$$D_{\\text{ideal}} = (1.6 \\,\\mu\\mathrm{g}/\\mathrm{kg}/\\mathrm{day}) \\times W$$\n$$D_{\\text{ideal}} = (1.6 \\,\\mu\\mathrm{g}/\\mathrm{kg}/\\mathrm{day}) \\times 70 \\,\\mathrm{kg} = 112 \\,\\mu\\mathrm{g}/\\mathrm{day}$$\nThis is the target dose that would be administered under ideal fasting conditions.\n\n**Step 2: Calculate the Adjusted Dose ($D_{\\text{adj}}$) to Compensate for Reduced Bioavailability**\n\nThe therapeutic objective is to ensure that the amount of levothyroxine absorbed by the patient remains the same, despite the interfering substance. Let $A$ represent the amount of drug absorbed.\n\nLet $F_{\\text{fasting}}$ be the absolute bioavailability of levothyroxine under fasting conditions. The amount absorbed from the ideal dose would be:\n$$A_{\\text{ideal}} = D_{\\text{ideal}} \\times F_{\\text{fasting}}$$\n\nThe problem states that when taken with calcium carbonate, the bioavailability is reduced to a fraction $f=0.72$ of the fasting bioavailability. Let the adjusted dose be $D_{\\text{adj}}$. The new bioavailability is $F_{\\text{impaired}} = f \\times F_{\\text{fasting}}$. The amount absorbed from this adjusted dose is:\n$$A_{\\text{adj}} = D_{\\text{adj}} \\times F_{\\text{impaired}} = D_{\\text{adj}} \\times (f \\times F_{\\text{fasting}})$$\n\nTo maintain therapeutic equivalence, we must have $A_{\\text{adj}} = A_{\\text{ideal}}$:\n$$D_{\\text{adj}} \\times (f \\times F_{\\text{fasting}}) = D_{\\text{ideal}} \\times F_{\\text{fasting}}$$\n\nThe absolute bioavailability term, $F_{\\text{fasting}}$, is a common factor on both sides of the equation and can be cancelled. This is logical, as the problem is one of relative bioavailability.\n$$D_{\\text{adj}} \\times f = D_{\\text{ideal}}$$\nSolving for the adjusted dose, $D_{\\text{adj}}$:\n$$D_{\\text{adj}} = \\frac{D_{\\text{ideal}}}{f}$$\n\nNow, we substitute the known values:\n$$D_{\\text{adj}} = \\frac{112 \\,\\mu\\mathrm{g}/\\mathrm{day}}{0.72}$$\n$$D_{\\text{adj}} \\approx 155.555... \\,\\mu\\mathrm{g}/\\mathrm{day}$$\n\nThe problem requires the final answer to be rounded to $4$ significant figures.\n$$D_{\\text{adj}} = 155.6 \\,\\mu\\mathrm{g}/\\mathrm{day}$$\n\nThis adjusted dose of $155.6 \\,\\mu\\mathrm{g}/\\mathrm{day}$, when taken with calcium carbonate, is calculated to deliver the same amount of absorbed levothyroxine as a $112 \\,\\mu\\mathrm{g}/\\mathrm{day}$ dose taken under fasting conditions.",
            "answer": "$$\n\\boxed{155.6}\n$$"
        },
        {
            "introduction": "Unlike the straightforward replacement strategy in hypothyroidism, initiating therapy for hyperthyroidism requires careful titration based on disease severity to safely and effectively control hormone overproduction. This exercise focuses on managing Graves' disease with methimazole, modeling a data-driven approach to selecting a starting dose. By using the degree of free thyroxine ($fT_4$) elevation as a quantitative marker of severity , you will practice balancing the need for rapid hormonal control against the risk of side effects, a core competency in managing thyrotoxicosis.",
            "id": "4905849",
            "problem": "A 34-year-old adult with newly diagnosed Graves hyperthyroidism presents with palpitations, weight loss, tremor, and a diffuse goiter. Laboratory testing confirms markedly elevated free thyroxine (free T4, denoted $fT_4$). The measured $fT_4$ is $64\\ \\text{pmol/L}$, and the laboratory upper limit of normal (denoted $\\text{ULN}$) is $19\\ \\text{pmol/L}$. The patient’s body weight is $83\\ \\text{kg}$. There is no significant hepatic disease, no baseline neutropenia, and no plan for immediate radioactive iodine therapy.\n\nUse the following accepted clinical facts to derive a starting methimazole dose that is both severity- and size-adjusted while remaining within standard safety limits:\n- In adults with Graves disease, initial methimazole dosing is titrated according to the biochemical severity of hyperthyroidism and body size; commonly used and well-tested dosing spans $0.2$ to $0.5\\ \\text{mg/kg/day}$, with higher values chosen for greater fold-elevations of $fT_4$ above the upper limit of normal.\n- For the purpose of this calculation, assume the per-kilogram starting dose increases linearly from $0.2\\ \\text{mg/kg/day}$ at a one-fold elevation ($fT_4 = 1 \\times \\text{ULN}$) to $0.5\\ \\text{mg/kg/day}$ at a four-fold elevation ($fT_4 = 4 \\times \\text{ULN}$). Clamp values below $1 \\times \\text{ULN}$ to $0.2\\ \\text{mg/kg/day}$ and above $4 \\times \\text{ULN}$ to $0.5\\ \\text{mg/kg/day}$.\n- Do not exceed a total daily dose of $40\\ \\text{mg/day}$, consistent with common adult starting-dose safety caps in American Thyroid Association (ATA) guidance.\n\nCompute the methimazole starting dose as a single real-valued number in milligrams per day. Express your answer in $\\text{mg/day}$, rounding to two significant figures.",
            "solution": "The problem statement is first subjected to a rigorous validation process.\n\n### Step 1: Extract Givens\nThe explicit data and conditions provided in the problem statement are as follows:\n- Patient Age: $34$ years\n- Patient Body Weight ($W$): $83\\ \\text{kg}$\n- Measured free thyroxine ($fT_4$): $64\\ \\text{pmol/L}$\n- Upper limit of normal for $fT_4$ ($\\text{ULN}$): $19\\ \\text{pmol/L}$\n- Per-kilogram methimazole dosing range ($D_{kg}$): $0.2\\ \\text{mg/kg/day}$ to $0.5\\ \\text{mg/kg/day}$\n- Dosing model: A linear relationship between the per-kilogram dose ($D_{kg}$) and the fold-elevation of $fT_4$ above its upper limit of normal ($F = \\frac{fT_4}{\\text{ULN}}$).\n- Boundary conditions for the linear model:\n  - At $F=1$, $D_{kg} = 0.2\\ \\text{mg/kg/day}$.\n  - At $F=4$, $D_{kg} = 0.5\\ \\text{mg/kg/day}$.\n- Clamping rules:\n  - For $F < 1$, the dose is clamped at $D_{kg} = 0.2\\ \\text{mg/kg/day}$.\n  - For $F > 4$, the dose is clamped at $D_{kg} = 0.5\\ \\text{mg/kg/day}$.\n- Safety constraint: The maximum total daily dose ($D_{max}$) must not exceed $40\\ \\text{mg/day}$.\n- Final answer requirement: Round the computed dose to two significant figures.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is assessed against the required criteria:\n- **Scientifically Grounded**: The problem is set in a realistic clinical context of managing Graves' disease, a common cause of hyperthyroidism. The specified laboratory values ($fT_4$, $\\text{ULN}$), patient weight, and dosing principles (weight-based, severity-adjusted dosing for methimazole, and a safety cap) are consistent with established medical practice and guidelines from endocrinology societies like the American Thyroid Association (ATA). Therefore, the problem is scientifically sound.\n- **Well-Posed**: All necessary numerical values and mathematical relationships are provided to calculate a unique starting dose. The problem defines a piecewise linear function for the dose calculation and a final inequality constraint (the safety cap), leading to a single, unambiguous solution. The problem is well-posed.\n- **Objective**: The problem is stated using precise, quantitative language. All parameters are explicitly defined, and the calculation rules are specified without ambiguity. There are no subjective or opinion-based statements. The problem is objective.\n\n### Step 3: Verdict and Action\nThe problem is scientifically grounded, well-posed, objective, and internally consistent. It is deemed **valid**. The solution process will now proceed.\n\n### Solution Derivation\nThe calculation of the appropriate methimazole starting dose proceeds in several steps.\n\n**1. Calculate the fold-elevation of free T4.**\nLet $F$ represent the fold-elevation of the patient's measured $fT_4$ level relative to the upper limit of normal, $\\text{ULN}$.\nThe given values are $fT_4 = 64\\ \\text{pmol/L}$ and $\\text{ULN} = 19\\ \\text{pmol/L}$.\n$$F = \\frac{fT_4}{\\text{ULN}} = \\frac{64}{19}$$\nThe numerical value is $F \\approx 3.3684$.\n\n**2. Determine the per-kilogram dose ($D_{kg}$).**\nThe problem specifies a linear relationship for $D_{kg}$ as a function of $F$ in the interval $F \\in [1, 4]$. Let this function be $D_{kg}(F) = mF + c$, where $m$ is the slope and $c$ is the y-intercept.\n\nWe are given two points on this line: $(F_1, D_{kg,1}) = (1, 0.2)$ and $(F_2, D_{kg,2}) = (4, 0.5)$.\nThe slope $m$ is calculated as:\n$$m = \\frac{\\Delta D_{kg}}{\\Delta F} = \\frac{D_{kg,2} - D_{kg,1}}{F_2 - F_1} = \\frac{0.5 - 0.2}{4 - 1} = \\frac{0.3}{3} = 0.1\\ \\frac{\\text{mg/kg/day}}{\\text{fold-elevation}}$$\nUsing the point-slope form with the point $(1, 0.2)$:\n$$D_{kg}(F) - 0.2 = 0.1 \\cdot (F - 1)$$\n$$D_{kg}(F) = 0.1 F - 0.1 + 0.2$$\n$$D_{kg}(F) = 0.1 F + 0.1$$\nThe calculated patient's fold-elevation $F = \\frac{64}{19}$ is approximately $3.3684$. Since $1 < \\frac{64}{19} < 4$, the patient falls within the linear range, and the clamping rules do not apply.\n\nWe now calculate the specific per-kilogram dose for this patient:\n$$D_{kg} = 0.1 \\cdot \\left(\\frac{64}{19}\\right) + 0.1 = \\frac{6.4}{19} + \\frac{1.9}{19} = \\frac{8.3}{19}\\ \\text{mg/kg/day}$$\n\n**3. Calculate the unconstrained total daily dose.**\nThe total daily dose, prior to applying the safety cap, is the per-kilogram dose multiplied by the patient's body weight, $W = 83\\ \\text{kg}$. Let this be $D_{unconstrained}$.\n$$D_{unconstrained} = D_{kg} \\times W = \\left(\\frac{8.3}{19}\\right) \\times 83 = \\frac{688.9}{19}\\ \\text{mg/day}$$\nThe numerical value is $D_{unconstrained} \\approx 36.25789\\ \\text{mg/day}$.\n\n**4. Apply the safety cap.**\nThe problem states a maximum total daily dose, $D_{max} = 40\\ \\text{mg/day}$. The final prescribed dose, $D_{final}$, is the minimum of the calculated dose and the maximum allowed dose.\n$$D_{final} = \\min(D_{unconstrained}, D_{max})$$\n$$D_{final} = \\min\\left(\\frac{688.9}{19}, 40\\right)$$\nSince $\\frac{688.9}{19} \\approx 36.25789$ is less than $40$, the calculated dose is within the safety limit.\n$$D_{final} = \\frac{688.9}{19}\\ \\text{mg/day}$$\n\n**5. Round to the specified significant figures.**\nThe problem requires the final answer to be rounded to two significant figures. The calculated value is approximately $36.25789...$.\nThe first two significant figures are $3$ and $6$. The subsequent digit is $2$, which is less than $5$, so we round down.\nThe final dose is $36\\ \\text{mg/day}$.",
            "answer": "$$\\boxed{36}$$"
        }
    ]
}